PPT-ODYSSEY FH I and II In FH I:

From baseline to 24 weeks the change in LDLC 488 for alirocumab vs 91 for placebo p lt 00001 The dose of alirocumab was uptitrated in 434 of participants

alirocumab weeks ldl placebo weeks alirocumab placebo ldl 0001 maintained baseline change participants reduction heterozygous hypercholesterolemia familial titrated dose

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/932827" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "ODYSSEY FH I and II In FH I:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.